Barbiturates and Pregnancy: Risks to Fetal Development

Barbiturates are sedative-hypnotics with high addiction potential and serious teratogenic risks.

Fetal Risks

  • Congenital malformations: Cardiac defects, neural tube defects, cleft lip/palate, microcephaly.
  • Growth restriction: Low birth weight, IUGR.
  • Neurodevelopmental: Cognitive deficits, learning disabilities, behavioral issues.
  • Neonatal withdrawal: Tremors, hyperreflexia, seizures, feeding difficulty, irritability (may last weeks).
  • Respiratory depression: At delivery if mother recently dosed.
  • Stillbirth: Increased risk with chronic use.

Mechanism

Barbiturates cross placenta, accumulate in fetal tissue, and induce hepatic enzymes (altering steroid metabolism). Chronic use depletes folate.

Clinical Guidance

  • Avoid in pregnancy; use safer alternatives (e.g., for epilepsy: levetiracetam, lamotrigine).
  • If already pregnant: Do not stop abruptly—risk of maternal/fetal withdrawal seizures. Taper under specialist supervision.
  • High-dose folate (4 mg/day) if continuation unavoidable.
  • Multidisciplinary care (OB, neurology, psychiatry, neonatology).

Preconception counseling is ideal for medication optimization.

Bulimia - Related Articles